Reactivation of Pulmonary Tuberculosis following Treatment of Myelofibrosis with Ruxolitinib

被引：17

作者：

Abidi, Maheen Z. ^{[1
]}

Haque, Javeria ^{[2
]}

Varma, Parvathi ^{[3
]}

Olteanu, Horatiu ^{[4
]}

Murthy, Guru Subramanian Guru ^{[5
]}

Dhakal, Binod ^{[5
]}

Hari, Parameswaran ^{[5
]}

机构：

[1] Univ Colorado, Dept Med, Div Infect Dis, Denver, CO USA

[2] Med Coll Wisconsin, Dept Med, Div Infect Dis, Milwaukee, WI 53226 USA

[3] Univ Birmingham, Sch Med, Birmingham, W Midlands, England

[4] Med Coll Wisconsin, Dept Pathol, Milwaukee, WI 53226 USA

[5] Med Coll Wisconsin, Dept Med, Div Hematol & Oncol, Milwaukee, WI 53226 USA

来源：

CASE REPORTS IN HEMATOLOGY | 2016年 / 2016卷

关键词：

D O I：

10.1155/2016/2389038

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Ruxolitinib is widely in use for treatment of myeloproliferative disorders. It causes inhibition of the Janus kinase (JAK) signal transducer and activation of transcription (STAT) pathway, which plays a key role in the underlying pathophysiology of myeloproliferative diseases. We describe a case of reactivation pulmonary tuberculosis in a retired physician while on treatment with ruxolitinib. We also review the literature on opportunistic infections following use of ruxolitinib. Our case highlights the importance of screening for latent tuberculosis in patients from highly endemic areas prior to start of therapy with ruxolitinib.

引用

页数：4

共 50 条

[1] Pulmonary tuberculosis reactivation following ruxolitinib treatment in a patient with primary myelofibrosis
Chen, Yen-Hao
Lee, Chen-Hsiang
Pei, Sung-Nan
[J]. LEUKEMIA & LYMPHOMA, 2015, 56 (05) : 1528 - 1529
[2] Tuberculosis reactivation related with ruxolitinib in a patient with primary myelofibrosis
Pepeler, Mehmet Sezgin
Ozkurt, Zubeyde Nur
Guzel, Ozlem Tunccan
Akyurek, Nalan
[J]. JOURNAL OF INFECTION IN DEVELOPING COUNTRIES, 2018, 12 (10): : 926 - 928
[3] Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis
Caocci, G.
Murgia, F.
Podda, L.
Solinas, A.
Atzeni, S.
La Nasa, G.
[J]. LEUKEMIA, 2014, 28 (01) : 225 - 227
[4] Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis
G Caocci
F Murgia
L Podda
A Solinas
S Atzeni
G La Nasa
[J]. Leukemia, 2014, 28 : 225 - 227
[5] Ruxolitinib In the Treatment of Myelofibrosis
Yang, Lily P. H.
Keating, Gillian M.
[J]. DRUGS, 2012, 72 (16) : 2117 - 2127
[6] RUXOLITINIB FOR THE TREATMENT OF MYELOFIBROSIS
Ostojic, A.
Vrhovac, R.
Verstovsek, S.
[J]. DRUGS OF TODAY, 2011, 47 (11) : 817 - 827
[7] A neutrophilic dermatosis following treatment of myelofibrosis with ruxolitinib: An emerging phenomenon?
Jiang, Melinda
Tran, Alain Khoi
Marshman, Gillian
[J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2021, 62 (04) : E607 - E609
[8] Use of rifampin for treatment of disseminated tuberculosis in a patient with primary myelofibrosis on ruxolitinib
Benoit Branco
David Metsu
Marine Dutertre
Bruno Marchou
Pierre Delobel
Christian Recher
Guillaume Martin-Blondel
[J]. Annals of Hematology, 2016, 95 : 1207 - 1209
[9] Use of rifampin for treatment of disseminated tuberculosis in a patient with primary myelofibrosis on ruxolitinib
Branco, Benoit
Metsu, David
Dutertre, Marine
Marchou, Bruno
Delobel, Pierre
Recher, Christian
Martin-Blondel, Guillaume
[J]. ANNALS OF HEMATOLOGY, 2016, 95 (07) : 1207 - 1209
[10] Ruxolitinib for pulmonary extramedullary hematopoiesis in myelofibrosis
Maccaferri, Monica
Leonardi, Giovanna
Marasca, Roberto
Colaci, Elisabetta
Paolini, Ambra
Soci, Francesco
Forghieri, Fabio
Potenza, Leonardo
Narni, Franco
Luppi, Mario
[J]. LEUKEMIA & LYMPHOMA, 2014, 55 (09) : 2207 - 2208

← 1 2 3 4 5 →